Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.79 |
| ▸ | VEGFA | P15692 | 12/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278202 | 0.89 | VEGFA (1.00) | EGLN1VEGFAALDH1A1KDM4ELMNA | |
| SCHEMBL273037 | 0.85 | EGLN1 (0.87) | EGLN1VEGFAALDH1A1KDM4ELMNA | |
| SCHEMBL272116 | 0.84 | VEGFA (0.85) | EGLN1VEGFAALDH1A1KDM4ELMNA | |
| SCHEMBL272076 | 0.84 | VEGFA (0.85) | EGLN1VEGFAALDH1A1KDM4ELMNA | |
| SCHEMBL273696 | 0.84 | EGLN1 (0.85) | EGLN1VEGFAKDM4ELMNAHTT | |
| SCHEMBL271963 | 0.84 | EGLN1 (0.85) | EGLN1VEGFAKDM4ELMNAHTT | |
| SCHEMBL277668 | 0.84 | EGLN1 (0.85) | EGLN1VEGFAKDM4ELMNAHTT | |
| SCHEMBL272320 | 0.83 | VEGFA (0.83) | EGLN1VEGFAALDH1A1KDM4EHTT | |
| SCHEMBL20763926 | 0.83 | VEGFA (0.83) | EGLN1VEGFAALDH1A1KDM4ELMNA | |
| SCHEMBL272359 | 0.81 | EGLN1 (0.81) | EGLN1VEGFAKDM4ELMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133894-B2 | N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones | AKEBIA THERAPEUTICS INC. (US) | 2012-03-13 | — | — | US | claimed |
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | WARNER CHILCOTT COMPANY, LLC | 2010-12-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305097-A1 | N-BENZYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES | IL17A, IFNG, CD4 | EGLN1 776/4885VEGFA 3152/4885ALDH1A1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.